Leukemia
Therapeutic area
Hematology
Rare disease
No
- Definition
- A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Leukemia
- Therapeutic area
- Hematology
- leukemia
- blood (leukemia)
- leukaemia (disease)
- leukemia
- leukemia (disease)
- leukemia, disease
- leukemia, malignant
- leukemias
- leukemias, general
- leukaemia NOS
- Severity
- Severe
- Hematology
- Oncology
- MONDO ID
- MONDO:0005059
- Parent condition
- MONDO:0044881
Related records
Broader conditions (10)
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
Narrower conditions (187)
- Acute basophilic leukemia
- Acute biphenotypic leukemia
- Acute erythroid leukemia
- Acute leukemia
- Acute leukemia of ambiguous lineage
- Acute lymphoblastic leukemia
- Acute megakaryoblastic leukemia
- Acute megakaryoblastic leukemia in adult
- Acute megakaryoblastic leukemia in down syndrome
- Acute megakaryoblastic leukemia without down syndrome
- Acute monocytic leukemia
- Acute myeloblastic leukemia with maturation
- Acute myeloblastic leukemia without maturation
- Acute myeloid leukemia
- Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
- Acute myeloid leukemia and myelodysplastic syndromes related to radiation
- Acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor
- Acute myeloid leukemia by FAB classification
- Acute myeloid leukemia with 11q23 abnormalities
- Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
Trials (5,736)
- "AIDA" Protocol (LAP 0493)
- "Geriatric Assessment Adapted" Therapy for Ph- ALL Elderly Patients
- "InDACtion" vs "3+7" Induction in AML
- "Peripheral Blood Dipeptidylpeptidase IV (CD26) Positive Leukemic Stem Cells in Chronic Myeloid Leukemia as a Diagnostic Marker"
- (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
- 05-001: Treatment of Acute Lymphoblastic Leukemia in Children
- 10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1
- 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
- 1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML)
- 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
- 2 Arm Study of Clofarabine IV in MDS Patients
- 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
- 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II
- 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- 2157GCCC:Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Dx AML
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
Approved drugs (13)
- Allopurinol
- Busulfan
- Cortisone acetate
- Dexamethasone
- Dexamethasone sodium phosphate
- Hydrocortisone
- Methylprednisolone acetate
- Methylprednisolone sodium succinate
- Prednisolone
- Prednisolone sodium phosphate
- Prednisone
- Rasburicase
- Revumenib citrate
Drugs in development (300)
- 4G7XH22 Phase 1
- A27.15 Phase 1
- Acalabrutinib Phase 1
- Acetaminophen Phase 2
- Aclarubicin Phase 2
- Acyclovir sodium Phase 1
- Adenosine Phase 1
- AEG-35156 Phase 2
- Aflibercept Phase 2
- AFM-11 Phase 1
- AHN-12 Phase 1
- Aldesleukin Phase 3
- Alemtuzumab Phase 3
- Alvocidib Phase 1
- Amifostine Phase 2
- Aminolevulinic acid hydrochloride Phase 2
- Aminopterin Phase 2
- Amphotericin B Phase 3
- Amsacrine Phase 3
- Anidulafungin Phase 2
Other linked drugs (3)
- Crisantaspase
- Dasatinib
- Ponatinib hydrochloride